Stockreport

GSK to partner with Vir for potential COVID-19 treatments, invest $250 mln [Reuters]

Vir Biotechnology, Inc.  (VIR) 
PDF GSK to partner with Vir for potential COVID-19 treatments, invest $250 million (Reuters) - British drugmaker GlaxoSmithKline Plc will invest $250 million in Vir Biotechn [Read more]